SenseTime and Sinopharm Capital have contributed to the oncology surgical device developer’s latest round, which will fund sales, marketing, product and technology improvement.

China-based cancer therapy equipment manufacturer Hygea Medical Technology secured RMB500m ($77m) in series C funding today from investors including image recognition technology producer SenseTime and pharmaceutical firm Sinopharm.

Venture capital firm China Growth Capital led the round, which included BioTrack Capital, Chengwei Chuangban, Grand Flight, Junyida Capital, Potential Capital, Sharewin Investment, Suiyong Capital, Yuanhui Capital and China Reform Holdings Corporation Fund, while Sinopharm invested through its Sinopharm Capital unit.

Founded in 2010, Hygea is working on devices designed to be…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn